Association between pre-existing chronic conditions and severity of first SARS-CoV-2 infection symptoms among adults living in Canada: a population-based survey analysis from January 2020 to August 2022.

Nicholas Cheta, Dianne Zakaria, Alain Demers, Peri Abdullah, Samina Aziz
Author Information
  1. Nicholas Cheta: Lifespan Chronic Diseases and Conditions Division (LCDC), Centre for Surveillance and Applied Research (CSAR), Health Promotion and Chronic Disease Prevention Branch (HPCDP), Public Health Agency of Canada (PHAC), Ottawa, ON, Canada. nicholas.cheta@phac-aspc.gc.ca.
  2. Dianne Zakaria: Lifespan Chronic Diseases and Conditions Division (LCDC), Centre for Surveillance and Applied Research (CSAR), Health Promotion and Chronic Disease Prevention Branch (HPCDP), Public Health Agency of Canada (PHAC), Ottawa, ON, Canada.
  3. Alain Demers: Lifespan Chronic Diseases and Conditions Division (LCDC), Centre for Surveillance and Applied Research (CSAR), Health Promotion and Chronic Disease Prevention Branch (HPCDP), Public Health Agency of Canada (PHAC), Ottawa, ON, Canada.
  4. Peri Abdullah: Lifespan Chronic Diseases and Conditions Division (LCDC), Centre for Surveillance and Applied Research (CSAR), Health Promotion and Chronic Disease Prevention Branch (HPCDP), Public Health Agency of Canada (PHAC), Ottawa, ON, Canada.
  5. Samina Aziz: Lifespan Chronic Diseases and Conditions Division (LCDC), Centre for Surveillance and Applied Research (CSAR), Health Promotion and Chronic Disease Prevention Branch (HPCDP), Public Health Agency of Canada (PHAC), Ottawa, ON, Canada.

Abstract

BACKGROUND: Individuals living with chronic conditions (CC) typically have a higher risk of more severe outcomes when exposed to infection. Although many studies have investigated the relationship between CCs and COVID-19 severity, they are generally limited to clinical or hospitalized populations. There is a need to estimate the impact of pre-existing CCs on the severity of acute SARS-CoV-2 infection symptoms among the general population.
METHODS: Data from the Canadian COVID-19 Antibody and Health Survey - Cycle 2, a population-based cross-sectional probability survey across 10 provinces capturing the COVID-19 experiences of respondents from January 2020 to August 2022, were used to assess whether pre-existing CCs increased the odds of more severe self-reported infection symptoms among adults living in Canada. Multivariable regression modelling identified which CCs were independently associated with more severe infection symptoms after adjusting for sex, age at infection, and other significant covariates.
RESULTS: Chronic lung disease (aOR���=���1.64, 95% CI: 1.09, 2.46), high blood pressure (aOR���=���1.35, 95% CI: 1.13, 1.62), weakened immune system (aOR���=���1.46, 95% CI: 1.08, 1.98), chronic fatigue syndrome or fibromyalgia (aOR���=���2.20, 95% CI: 1.39, 3.50), and arthritis (aOR���=���1.28, 95% CI: 1.04, 1.56) were associated with a higher odds of more severe infection, whereas osteoporosis (aOR���=���0.58, 95% CI: 0.39, 0.87) was associated with a lower odds. Limiting modelling to adults with confirmed SARS-CoV-2 infections affected some of the variables retained and adjusted associations.
CONCLUSION: Our findings contribute to a growing evidence base of associations between pre-existing CCs and adverse outcomes after SARS-CoV-2 infection. Identifying factors associated with more severe infection allows for more targeted prevention strategies and early interventions that can minimize the impact of infection.

Keywords

References

  1. Sleep Breath. 2021 Jun;25(2):1155-1157 [PMID: 32989673]
  2. Int J Environ Res Public Health. 2020 Aug 27;17(17): [PMID: 32867287]
  3. Lancet Reg Health Eur. 2023 Oct 13;35:100747 [PMID: 38115964]
  4. BMC Public Health. 2023 Aug 29;23(1):1655 [PMID: 37644418]
  5. Gastroenterology. 2020 Oct;159(4):1541-1544.e2 [PMID: 32479824]
  6. OTO Open. 2021 May 17;5(2):2473974X211016283 [PMID: 34036239]
  7. J Multidiscip Healthc. 2016 May 04;9:211-7 [PMID: 27217764]
  8. BMJ. 2020 Oct 20;371:m3731 [PMID: 33082154]
  9. Clin Neurol Neurosurg. 2021 Jan;200:106349 [PMID: 33172719]
  10. Neurology. 2022 May 10;98(19):e1886-e1892 [PMID: 35338078]
  11. PLoS One. 2020 Nov 17;15(11):e0241955 [PMID: 33201896]
  12. Lancet Diabetes Endocrinol. 2021 Feb;9(2):82-93 [PMID: 33357491]
  13. Am J Cardiol. 2022 Nov 15;183:16-23 [PMID: 36175254]
  14. J Pers Med. 2023 Jan 17;13(2): [PMID: 36836400]
  15. J Gerontol B Psychol Sci Soc Sci. 2021 Jan 18;76(2):e30-e37 [PMID: 32674138]
  16. Sci Rep. 2024 Jul 31;14(1):17738 [PMID: 39085367]
  17. Lancet. 2022 Mar 5;399(10328):924-944 [PMID: 35202601]
  18. Inflammopharmacology. 2023 Apr;31(2):633-651 [PMID: 36849853]
  19. Sci Prog. 2021 Apr-Jun;104(2):368504211019854 [PMID: 34061685]
  20. Sci Rep. 2022 Nov 17;12(1):19818 [PMID: 36396860]
  21. J Orthop Surg Res. 2024 Sep 16;19(1):568 [PMID: 39285484]
  22. Lancet Infect Dis. 2021 Aug;21(8):1184-1191 [PMID: 33662324]
  23. Diabetes Ther. 2021 Aug;12(8):2223-2239 [PMID: 34275115]
  24. Int J Infect Dis. 2021 Nov;112:247-253 [PMID: 34517049]
  25. Respir Med. 2023 Jan;206:107064 [PMID: 36459955]
  26. PLoS One. 2021 Dec 30;16(12):e0261772 [PMID: 34968398]
  27. BMC Gastroenterol. 2024 Nov 23;24(1):425 [PMID: 39580396]
  28. Lancet Rheumatol. 2022 Nov;4(11):e765-e774 [PMID: 36118532]
  29. Front Endocrinol (Lausanne). 2022 Oct 11;13:1025699 [PMID: 36303877]
  30. Nature. 2020 Aug;584(7821):430-436 [PMID: 32640463]
  31. BMJ Evid Based Med. 2022 Oct;27(5):263-273 [PMID: 34933924]
  32. BMJ Open. 2021 May 13;11(5):e044684 [PMID: 33986052]
  33. Lancet Glob Health. 2022 Mar;10(3):e326-e328 [PMID: 35180408]
  34. BMJ Glob Health. 2023 Jul;8(7): [PMID: 37419502]
  35. JAMA Psychiatry. 2021 Nov 1;78(11):1208-1217 [PMID: 34313711]
  36. CMAJ. 2023 Aug 14;195(31):E1030-E1037 [PMID: 37580072]
  37. Open Heart. 2023 Dec 14;10(2): [PMID: 38097365]
  38. PLoS One. 2022 Jun 22;17(6):e0268688 [PMID: 35731726]
  39. Obesity (Silver Spring). 2022 May;30(5):999-1003 [PMID: 35226399]
  40. BMC Infect Dis. 2021 Aug 21;21(1):855 [PMID: 34418980]
  41. Mol Psychiatry. 2022 Feb;27(2):1248-1255 [PMID: 34873324]
  42. BMJ Glob Health. 2023 Dec 14;8(12): [PMID: 38097276]
  43. Front Immunol. 2022 Oct 20;13:949787 [PMID: 36341457]
  44. Curr Probl Cardiol. 2020 Aug;45(8):100617 [PMID: 32402515]
  45. J Ovarian Res. 2020 Nov 24;13(1):137 [PMID: 33234144]
  46. J Alzheimers Dis. 2022;87(2):701-710 [PMID: 35275548]

MeSH Term

Humans
COVID-19
Canada
Male
Female
Adult
Middle Aged
Cross-Sectional Studies
Chronic Disease
Severity of Illness Index
Aged
Young Adult
SARS-CoV-2
Adolescent
Health Surveys
Risk Factors

Word Cloud

Created with Highcharts 10.0.0infection195%CI:severeCCsSARS-CoV-2chronicCOVID-19severitypre-existingsymptomsassociatedaOR���=���1livingconditionsamongsurveyoddsadultshigheroutcomesimpact2population-basedcross-sectionalJanuary2020August2022Canadamodelling46390associationsBACKGROUND:IndividualsCCtypicallyriskexposedAlthoughmanystudiesinvestigatedrelationshipgenerallylimitedclinicalhospitalizedpopulationsneedestimateacutegeneralpopulationMETHODS:DataCanadianAntibodyHealthSurvey-Cycleprobabilityacross10provincescapturingexperiencesrespondentsusedassesswhetherincreasedself-reportedMultivariableregressionidentifiedindependentlyadjustingsexagesignificantcovariatesRESULTS:Chroniclungdisease6409highbloodpressure351362weakenedimmunesystem0898fatiguesyndromefibromyalgiaaOR���=���220350arthritis280456whereasosteoporosisaOR���=���05887lowerLimitingconfirmedinfectionsaffectedvariablesretainedadjustedCONCLUSION:findingscontributegrowingevidencebaseadverseIdentifyingfactorsallowstargetedpreventionstrategiesearlyinterventionscanminimizeAssociationfirstCanada:analysisCCAHS-2multivariablemodeling

Similar Articles

Cited By

No available data.